| |
|
|
|
|
|
|
|||
|
Blood, 13 August 2009, Vol. 114, No. 7, pp. 1417-1422. Prepublished online as a Blood First Edition Paper on June 12, 2009; DOI 10.1182/blood-2009-04-215269.
THROMBOSIS AND HEMOSTASIS Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study1 Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; 2 Unit of Genomics of Complex Diseases, Research Institute, and 3 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 4 Clinical Trials Service and Epidemiological Studies Unit (CTSU), University of Oxford, Oxford, United Kingdom; 5 Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6 Department of Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom; 7 Department of Cardiovascular Research, MarioNegri Institute for Pharmacological Research, Milano, Italy; 8 Leibniz-Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany; and 9 Department of Population Genetics, Southwest Foundation for Biomedical Research, San Antonio, TX
Total plasma homocysteine concentration (tHcy) is a biomarker for atherothrombotic disease, but causality remains uncertain. Polymorphisms in the genes involved in methionine metabolism explain only a small fraction of the heritability of tHcy levels. In a genome-wide association study, we examined the genetic determinants of tHcy using a 2-stage design. First, 283 437 single nucleotide polymorphisms (SNPs) were tested for association with tHcy in 387 persons recruited from 21 large Spanish families. Of those, 17 SNPs showed equal or stronger association with tHcy level compared with the MTHFR 677C>T SNP (β = 0.10, P = .0001). Second, a replication analysis of these 17 SNPs was performed in patients with premature myocardial infarction (n = 1238). Novel associations were found for SNPs near the ZNF366 gene (lead SNP rs7445013; discovery stage: adjusted β = –0.12, P = 5.30 x 10–6, replication stage: adjusted β = –0.13, P = .004) and the PTPRD gene (lead SNP rs973117; discovery stage: adjusted β = 0.11, P = 5.5 x 10–6, replication stage: adjusted β = 0.10, P = .005). These associations were independent of known confounders, including creatinine clearance and plasma fibrinogen concentration. Our findings implicate novel pathways in homocysteine metabolism, and highlight the need for investigation of the associated genes in the etiology of vascular diseases.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||